Citius holder reports 9.9% ownership stake
Citius Pharmaceuticals’ major shareholder updates its ownership.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Citius Pharmaceuticals’ major shareholder updates its ownership. CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. report beneficial ownership of 2,394,725 shares of Citius common stock, representing 9.9% of the outstanding shares as of December 31, 2025.
The position includes 799,934 common shares plus additional shares issuable from warrants, which are subject to 4.99% and 9.99% beneficial ownership limits. The reporting parties state the securities are not held for the purpose of changing or influencing control of Citius.
Insights
Large investor reports a 9.9% non-control stake in Citius.
CVI Investments and its manager Heights Capital Management disclose beneficial ownership of 2,394,725 Citius shares, or 9.9% of the company’s common stock as of December 31, 2025. This combines 799,934 shares with additional shares underlying warrants.
The warrants are structured with 4.99% and 9.99% ownership caps, which limit how many shares can be exercised if doing so would push their beneficial stake above those thresholds. This helps keep reported ownership just under the 10% line that can trigger additional regulatory obligations.
The investors certify the position is not intended to change or influence control of Citius Pharmaceuticals. Future amendments to this Schedule 13G/A would indicate if the percentage holding or intent changes, but such developments would appear only in subsequent regulatory disclosures.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Citius Pharmaceuticals (CTXR) do CVI Investments and Heights Capital report?
Who are the reporting persons in this Citius Pharmaceuticals (CTXR) Schedule 13G/A?
Does CVI Investments’ 9.9% Citius (CTXR) stake seek to influence control of the company?
What ownership limits apply to the Citius (CTXR) warrants held by CVI Investments?
AI-generated analysis. How Rhea-AI works. Not financial advice.